Iressa Versus Docetaxel (Taxotere)

Study identifier:D791GC00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer who have Previously Received Platinum-Based Chemotherapy

Medical condition

Non-Small-Cell Lung Carcinoma

Phase

Phase 3

Healthy volunteers

No

Study drug

Gefitinib, Docetaxel

Sex

All

Actual Enrollment

1440

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2004
Primary Completion Date: 01 Mar 2007
Study Completion Date: 01 Oct 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria